Protocols
CARNABIOSCIENCES-C1763102 Phase I OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
MEI-ME-522-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
MERCK-MK2140-006-CLL-NHL Phase II OPEN TO ACCRUAL
A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies
NURIX-NX-5948-301 Phase I OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
SCHRODINGER-SGR-1505-101 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies